APA (7th ed.) Citation

Papadopoulos, K. P., Laurie, S. A., Spira, A., Fu, S., Hamilton, E., Ma, B., . . . Hamid, O. (2023). 741 TWT-101: A first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies. Journal for immunotherapy of cancer, 11(Suppl 1), A835. https://doi.org/10.1136/jitc-2023-SITC2023.0741

Chicago Style (17th ed.) Citation

Papadopoulos, Kyriakos P., et al. "741 TWT-101: A First-in-clinic Study of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as Single Agent or Combined with Pembrolizumab in Subjects with Advanced Solid Malignancies." Journal for Immunotherapy of Cancer 11, no. Suppl 1 (2023): A835. https://doi.org/10.1136/jitc-2023-SITC2023.0741.

MLA (9th ed.) Citation

Papadopoulos, Kyriakos P., et al. "741 TWT-101: A First-in-clinic Study of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as Single Agent or Combined with Pembrolizumab in Subjects with Advanced Solid Malignancies." Journal for Immunotherapy of Cancer, vol. 11, no. Suppl 1, 2023, p. A835, https://doi.org/10.1136/jitc-2023-SITC2023.0741.